Shattuck Labs Inc (NASDAQ:STTK) — Market Cap & Net Worth
Market Cap & Net Worth: Shattuck Labs Inc (STTK)
Shattuck Labs Inc (NASDAQ:STTK) has a market capitalization of $244.26 Million ($244.26 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15835 globally and #3748 in its home market, demonstrating a -9.54% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shattuck Labs Inc's stock price $5.88 by its total outstanding shares 63279843 (63.28 Million). Also see Shattuck Labs Inc assets under control for a full breakdown of the balance sheet.
Shattuck Labs Inc Market Cap History: 2020 to 2026
Shattuck Labs Inc's market capitalization history from 2020 to 2026. Data shows change from $3.32 Billion to $372.09 Million (-18.17% CAGR). Also see Shattuck Labs Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Shattuck Labs Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #433 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1549 of 3165 |
Weight: Shattuck Labs Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Shattuck Labs Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shattuck Labs Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Shattuck Labs Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
13.38x
Shattuck Labs Inc's market cap is 13.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.32 Billion | $9.93 Million | -$35.44 Million | 333.85x | N/A |
| 2021 | $538.51 Million | $30.02 Million | -$44.97 Million | 17.94x | N/A |
| 2022 | $145.54 Million | $652.00K | -$100.56 Million | 223.23x | N/A |
| 2023 | $451.19 Million | $1.66 Million | -$87.30 Million | 272.29x | N/A |
| 2024 | $76.57 Million | $5.72 Million | -$75.41 Million | 13.38x | N/A |
Competitor Companies of STTK by Market Capitalization
Companies near Shattuck Labs Inc in the global market cap rankings as of September 18, 2026. Review STTK intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Shattuck Labs Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Shattuck Labs Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Shattuck Labs Inc's market cap moved from $3.32 Billion to $ 372.09 Million, with a yearly change of -18.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $372.09 Million | +61.10% |
| 2025 | $230.97 Million | +201.65% |
| 2024 | $76.57 Million | -83.03% |
| 2023 | $451.19 Million | +210.00% |
| 2022 | $145.54 Million | -72.97% |
| 2021 | $538.51 Million | -83.76% |
| 2020 | $3.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Shattuck Labs Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $244.26 Million USD |
| MoneyControl | $244.26 Million USD |
| MarketWatch | $244.26 Million USD |
| marketcap.company | $244.26 Million USD |
| Reuters | $244.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shattuck Labs Inc
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inf… Read more